CHINA BIO INDUSTRY EXPLOSION ! WHAT ARE YOU WAITING FOR? COME TO CHINA, SEE THE CHANGE!
Recently, breakthroughs in China’s bio-industry have spread frequently
- Monoclonal antibodies to Terepril monoclonal antibody and Sindelimab, the PD1 drug of Junshi Biology, are on the market in China, respectively.
- Five of them have received IND approval in China, and about 30 have submitted applications for IND approval. With the continuous standardization of the policy of the cell therapy industry in China, 2019 is an important year.
- Breakthrough Records of Financing News for Bio-industry Enterprises
- Diagnosis in the second half of 2018, Fuel Stone Medicine was approved as “the first certificate of NGS in China”, and after that, Noah Origin, Nanjing Shihe and Xiamen Aide were approved as multi-target NGS tumor kits.
- In the second half of 2018, Wondfo and Biocartis Company established a joint venture, and KH Biology cooperated with Seegene from Korea.
- Domestic molecular diagnostics and gene testing companies cooperate frequently with overseas companies to promote the commercialization of molecular diagnostics in the field of cancer in China.
Based on the progress of China’s bio-industry in 2018, the 4th EBC came into being. China’s veteran bio-industry Congress will be held in Nanjing, the ancient capital of China, from March 1 to 3. Welcome the global bio-industry related enterprises to come.
2019 ENMORE BIO CONFERENCE
ORGNIZATOR: ENMORE HEALTHECARE
CO-HOST：3S Bio, 3D MED, FosunKite, IQVIA, I-MAB,Hrain, Dian Diagnostics,
- 9th Antibody Drugs & Novel Biological Summit
- 7th Molecular Diagnostics Summit
- 5th Immunotherapy Industry Summit
- 2nd Financing and Investment leadership Summit
108+ speech slots
5+ Industry analysis and roundtable
150+ Special guests
200+ Booth (CROCMO area, meeting area)
Antibody and Novel
“China Vision-New drug development and R&D strategy”
LianshanZhang, VP&GlobalR&D director, Jiangsu HengruiPharma
“How to choose partners to promote product process”
“Engineer CAR-T cells for improving cancer immunotherapy”
YarongLiu, R&D Director, HRAIN Biotechnology
YanniLin, CTO & Co-founder, Cure Genetics Co.
“China Molecular Diagnosis Industry Status and Future Market Growth from a Global View”
Chun Wu, CEO, BCG
“Development and application of molecular diagnostic products in vitro”
Tang Jiang, Chief Technical, Dian Diagnostics
||Jiangsu Provincial Inspection Center
|West China Hospital
For more information please contact (Deadline 30th, Jan, 2019):
Tel: +86 (0) 21 51552421